Welcome to our dedicated page for Alnylam Pharmaceuticals news (Ticker: ALNY), a resource for investors and traders seeking the latest updates and insights on Alnylam Pharmaceuticals stock.
Alnylam Pharmaceuticals develops and commercializes RNA interference (RNAi) therapeutics, with news centered on its approved medicines, TTR franchise, clinical pipeline and financial performance. Company updates commonly address AMVUTTRA/vutrisiran and ONPATTRO/patisiran for transthyretin-mediated amyloidosis, GIVLAARI/givosiran for acute hepatic porphyria, OXLUMO/lumasiran for primary hyperoxaluria type 1, and partner-commercialized RNAi medicines.
Recurring developments include quarterly product revenue reports, guidance, clinical and real-world data for ATTR-CM and other cardiovascular programs, pipeline progress across cardio-metabolic disease, neuroscience and hematology, disease-awareness collaborations, and investor conference presentations. Alnylam also reports on its Alnylam 2030 strategy and commercialization of RNAi medicines in global markets.
Alnylam Pharmaceuticals has announced the start of the KARDIA-2 Phase 2 study, assessing zilebesiran, an investigational RNAi therapeutic for hypertension management. This global trial will enroll 800 adults whose blood pressure is inadequately controlled by existing medications. The primary endpoint focuses on changes in 24-hour mean systolic blood pressure after three months. The study aims to address the rising prevalence of hypertension, projected to increase by 20% by 2025, highlighting Alnylam's commitment to innovative therapies for unmet needs in hypertension.
Alnylam Pharmaceuticals announced positive results from the ILLUMINATE-C Phase 3 study of lumasiran for treating advanced primary hyperoxaluria type 1 (PH1). This RNAi therapeutic showed significant plasma oxalate reductions in patients with chronic kidney disease, achieving decreases of 33% and 42% in two patient cohorts. These results highlight its efficacy in reducing oxalate levels, essential for preventing complications like systemic oxalosis. Moreover, lumasiran had an acceptable safety profile, with mild injection site reactions being the most common adverse event.
Summary not available.
Alnylam Pharmaceuticals reported a significant Q3 2021 revenue of $167 million for its products ONPATTRO, GIVLAARI, and OXLUMO. The company highlighted promising 18-month results from the HELIOS-A Phase 3 study of vutrisiran in patients with hATTR amyloidosis. Global net product revenues for ONPATTRO rose 6% to $120 million, while GIVLAARI grew 4% to $32 million. However, OXLUMO saw a 9% decline in revenue. Alnylam reaffirmed its 2021 guidance of $640-$665 million in revenues and announced a leadership transition from CEO John Maraganore to Yvonne Greenstreet.
Alnylam Pharmaceuticals announces a leadership transition with CEO John Maraganore passing the reins to Yvonne Greenstreet by year-end 2021. Maraganore, a founding figure since 2002, has led the development of RNAi therapeutics, contributing to the approval of four medicines in 25 countries. Greenstreet, currently President and COO, brings significant experience and will step into her new role while Maraganore continues as a consultant until March 2022. The Board expressed strong confidence in Greenstreet's leadership to advance Alnylam’s P5x25 strategy.
Alnylam Pharmaceuticals announced that the HELIOS-A Phase 3 study of vutrisiran met all 18-month secondary endpoints. Significant improvements were observed in neuropathy, quality of life, gait speed, nutritional status, and overall disability compared to external placebo data. Additionally, vutrisiran showed positive exploratory endpoint results, including improved NT-proBNP levels and technetium uptake, indicating reduced cardiac amyloid burden. The drug has an encouraging safety profile, with minimal discontinuations due to adverse events. Full results are expected to be presented at an upcoming medical conference.
Alnylam Pharmaceuticals (NASDAQ: ALNY) will announce its third-quarter financial results for 2021 on October 28, 2021, before U.S. markets open. The company will host a conference call at 8:30 am ET to discuss results and future expectations. Investors can access the live call by dialing 877-312-7507 (domestic) or +1-631-813-4828 (international), with a replay available later in the day. Alnylam develops innovative RNA interference (RNAi) therapeutics aimed at addressing severe diseases, with a commitment to delivering transformative medicines through its ongoing pipeline.
Alnylam Pharmaceuticals (NASDAQ: ALNY) has launched the Alnylam Challengers program, committing $1 million to Acumen America to enhance health equity initiatives. This partnership aims to assist 75 million individuals in the U.S. by 2024 by tackling health disparities due to poverty and discrimination. The program includes a Social Investment Portfolio, an Advisory Corps for expert volunteering, and cross-sector Convenings to address health equity issues. Alnylam emphasizes its corporate responsibility and investment in sustainable health solutions.
Alnylam Pharmaceuticals announced promising pre-clinical research at the 17th Annual Meeting of the Oligonucleotide Therapeutics Society, showcasing innovations in RNAi therapeutics. Their hexadecyl (C16) conjugate demonstrates over 90% target knockdown potential in the CNS with an annual dosing regimen. The presentation also highlighted the IKARIA platform, which facilitates effective siRNA delivery. Additionally, pre-clinical data on ALN-APP for early-onset Alzheimer's Disease showed promising results, with plans for a clinical trial application later this year.
Alnylam Pharmaceuticals (Nasdaq: ALNY) will present a company overview at the Chardan Virtual 5th Annual Genetic Medicines Conference on Tuesday, October 5, 2021, at 2:30 pm ET. The presentation will be accessible via a live audio webcast on the Investors section of Alnylam's website, with a replay available within 48 hours post-event. Alnylam is a leader in RNA interference therapeutics, developing innovative treatments for rare diseases and more, including commercial products like ONPATTRO®, GIVLAARI®, and OXLUMO®. The company aims to transform medicine through its robust RNAi platform.